Loading...

FITC anti-human/mouse Granzyme B Antibody FITC anti-human/mouse Granzyme B Antibody

Pricing & Availability
Clone
GB11 (See other available formats)
Regulatory Status
RUO
Other Names
Granzyme-2, serine protease B, CCP1, Asp-ase, CTLA-1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
A_GB11_FITC_082409
Human peripheral blood lymphocytes surface stained with CD8 PE, then intracellular stained with GB11 FITC
  • A_GB11_FITC_082409
    Human peripheral blood lymphocytes surface stained with CD8 PE, then intracellular stained with GB11 FITC
  • B_GB11_FITC_082409
    Human peripheral blood lymphocytes surface stained with CD8 PE, then intracellular stained with mouse IgG1 FITC isotype control
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
515403 25 tests DKK796
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Granzyme B is a 32 kD serine protease, also known as granzyme-2, serine protease B, CCP1, Asp-ase, and CTLA-1. Granzyme B is abundantly stored in the granules of cytotoxic T lymphocytes and NK cells. Low level of expression has been reported in granulocytes, B cells, and activated dendritic cells. Granzyme B is crucial for rapid induction of cell death and apoptosis through interaction with mannose-6-phosphate receptor.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse
Reported Reactivity
Rat
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application References
  1. Wever PC, et al. 1998. Immunology. 93:383
  2. Arens R, et al. 2004. J. Exp. Med. 199:1595
  3. Lima M, et al. 2003. Am. J. Pathol. 163:763
  4. Wiede F, et al. 2014. J Autoimmun. 53:105. PubMed
  5. Baker GF, et al. 2014. Cancer Res. 74:5079. PubMed
  6. Nacer A, et al. 2014. PLoS Pathog. 10:1004528. PubMed
  7. Sharma SK, et al. 2015. J Immunol. 194:5529. PubMed
Product Citations
  1. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  2. Xiao C, et al. 2023. Nat Aging. 3:418. PubMed
  3. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  4. Ajith A, et al. 2021. Front Immunol. 12:687715. PubMed
  5. Xin B, et al. 2022. Hepatology. 76:630. PubMed
  6. Vorkas CK, et al. 2022. J Immunol. 208:1042. PubMed
  7. McMurray JL, et al. 2022. Cell Rep. 39:110858. PubMed
  8. Tan TCJ, et al. 2022. Nat Commun. 13:7796. PubMed
  9. An HW, et al. 2022. Cell Rep. 41:111878. PubMed
  10. Lin YH 2023. Immunity. 56(1):207-223.e8. PubMed
  11. Sieow JL, et al. 2023. Int J Mol Sci. 24: . PubMed
  12. Kuehm LM, et al. 2021. Cancer Immunol Res. 9:227. PubMed
  13. Drijvers JM, et al. 2021. Cancer Immunol Res. 9:184. PubMed
  14. Khojandi N, et al. 2021. Cancer Immunol Res. 9:214. PubMed
  15. Deng G, et al. 2022. J Immunother Cancer. 10:. PubMed
  16. Ou W, et al. 2023. Nat Commun. 14:392. PubMed
  17. Cheng MI, et al. 2023. Nat Immunol. 24:780. PubMed
  18. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  19. Baker G, et al. 2014. Cancer Res. 74:5079. PubMed
  20. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  21. Wang W, et al. 2022. World J Gastrointest Oncol. 14:1124. PubMed
  22. van Vloten JP, et al. 2022. J Immunother Cancer. 10:. PubMed
  23. AbuEid M, et al. 2021. iScience. 24(6):102653. PubMed
  24. Donnarumma T, et al. 2016. Cell Rep. 17:1571-1583. PubMed
  25. Shen T, et al. 2019. Cell Death Discov. 5:123. PubMed
  26. Huang X, et al. 2019. Cancer Immunol Res. 1.388888889. PubMed
  27. Leeansyah E, et al. 2015. PLoS Pathog. 11: 1005072. PubMed
  28. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  29. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  30. Ron–Harel N, et al. 2019. Cell Rep. 28:3011. PubMed
  31. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  32. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  33. Figueroa-Romero C, et al. 2022. Front Immunol. 13:773288. PubMed
  34. Di Blasi D, et al. 2019. Cell Mol Gastroenterol Hepatol. 0.510416667. PubMed
  35. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  36. Rafiq S, et al. 2018. Nat Biotechnol. 36:847. PubMed
  37. Peng Z, et al. 2021. STAR Protocols. 2(2):100595. PubMed
  38. Kramer KJ, et al. 2022. Nat Commun. 13:3466. PubMed
  39. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  40. Wu W, et al. 2020. Oncol Lett. 0.91875. PubMed
  41. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  42. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  43. Jiang P, et al. 2021. Nat Methods. 18:1181. PubMed
  44. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  45. Islas-Vazquez L, et al. 2020. Biology (Basel). 9:00. PubMed
  46. Kreutmair S, et al. 2021. Immunity. . PubMed
  47. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  48. Lucas C, et al. 2021. Nature. Online ahead of print. PubMed
  49. Adams NM et al. 2018. Immunity. 48(6):1172-1182 . PubMed
  50. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  51. Diaz–Salazar C, et al. 2020. Cell Rep. 32:108186. PubMed
  52. Fujigaki J, et al. 2015. PLoS One. 10: 0132521. PubMed
  53. Bastiaens G, et al. 2016. Am J Trop Med Hyg. 94: 663 - 673. PubMed
  54. Wiedemann GM, et al. 2020. Cell Rep. 33:108498. PubMed
  55. Huang CH, et al. 2020. Adv Ther (Weinh). 3:. PubMed
  56. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  57. Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed
  58. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  59. Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed
  60. Vardam-Kaur T, et al. 2021. Oncotarget. 12:2051. PubMed
  61. Xu S, et al. 2021. Immunity. . PubMed
  62. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  63. Bradley T et al. 2018. Cell. 175(2):387-399 . PubMed
  64. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  65. Luo Y, et al. 2021. Nat Commun. 12:3913. PubMed
  66. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  67. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  68. Leclerc M, et al. 2019. Nat Commun. 10:3345. PubMed
  69. Su S et al. 2018. Cell. 175(2):442-457 . PubMed
  70. Jeng MY, et al. 2018. J Exp Med. 215:51. PubMed
  71. Peluso MJ, et al. 2021. Cell Rep. 36:109518. PubMed
  72. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  73. Prado-Garcia H, et al. 2017. Cancer Immunol Immunother. 10.1007/s00262-017-1979-x. PubMed
  74. Wiede F, et al. 2014. J Autoimmun. 53:105. PubMed
  75. Kmieciak M, et al. 2011. J Immunol. 187:708. PubMed
  76. Zhang J, et al. 2018. Nature. 553:91. PubMed
  77. Kumagai S, et al. 2020. Immunity. 53(1):187-203.e8. PubMed
  78. Sagebiel AF, et al. 2019. Nat Commun. 10:975. PubMed
  79. Lettau M, et al. 2018. Int Immunol. 30:215. PubMed
  80. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  81. Thieme CJ, et al. 2020. Cell Rep Med. 1:100092. PubMed
  82. Yu M, et al. 2021. Molecular Cell. 81(6):1216-1230.e9. PubMed
  83. Maleki KT, et al. 2021. Cell Reports Medicine. 2(3):100220. PubMed
  84. Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed
  85. Dhar P, et al. 2021. Commun Biol. 4:905. PubMed
  86. Chen RH, et al. 2021. Front Immunol. 11:594775. PubMed
  87. Kansy BA, et al. 2017. Cancer Res. 77:6353. PubMed
  88. Hu X, et al. 2020. Neoplasia. 1.290972222. PubMed
  89. Sheppard S, et al. 2021. Cell Reports. 35(9):109210. PubMed
  90. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  91. Ajith A, et al. 2019. FASEB J. 33:5220. PubMed
  92. Geary CD et al. 2018. Cell reports. 24(8):1949-1957 . PubMed
  93. Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed
  94. DiMarco AV, et al. 2022. Cancer Immunol Res. 10:70. PubMed
  95. McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed
  96. Li Q, et al. 2022. J Biol Chem. :101753. PubMed
  97. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  98. Vonderhaar EP, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:41. PubMed
  99. Ruth JH, et al. 2021. JCI Insight. 6:e145662. PubMed
  100. Loo Yau H, et al. 2021. STAR Protocols. 2(2):100549. PubMed
  101. Loo Yau H, et al. 2021. Molecular Cell. 81(7):1469-1483.e8. PubMed
  102. Dubrot J, et al. 2021. Immunity. 54(3):571-585.e6. PubMed
  103. Durand J, et al. 2015. J Immunol. 195: 5035 - 5044. PubMed
  104. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  105. Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed
  106. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
  107. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  108. Carrion B, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  109. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
  110. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
  111. Gorby C, et al. 2020. Sci Signal. :13. PubMed
  112. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  113. Xiao C, et al. 2023. Nat Aging. 3:418. PubMed
  114. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  115. Ajith A, et al. 2021. Front Immunol. 12:687715. PubMed
  116. Xin B, et al. 2022. Hepatology. 76:630. PubMed
  117. Vorkas CK, et al. 2022. J Immunol. 208:1042. PubMed
  118. McMurray JL, et al. 2022. Cell Rep. 39:110858. PubMed
  119. Tan TCJ, et al. 2022. Nat Commun. 13:7796. PubMed
  120. An HW, et al. 2022. Cell Rep. 41:111878. PubMed
  121. Lin YH 2023. Immunity. 56(1):207-223.e8. PubMed
  122. Sieow JL, et al. 2023. Int J Mol Sci. 24: . PubMed
  123. Kuehm LM, et al. 2021. Cancer Immunol Res. 9:227. PubMed
  124. Drijvers JM, et al. 2021. Cancer Immunol Res. 9:184. PubMed
  125. Khojandi N, et al. 2021. Cancer Immunol Res. 9:214. PubMed
  126. Deng G, et al. 2022. J Immunother Cancer. 10:. PubMed
  127. Ou W, et al. 2023. Nat Commun. 14:392. PubMed
  128. Cheng MI, et al. 2023. Nat Immunol. 24:780. PubMed
  129. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  130. Baker G, et al. 2014. Cancer Res. 74:5079. PubMed
  131. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  132. Wang W, et al. 2022. World J Gastrointest Oncol. 14:1124. PubMed
  133. van Vloten JP, et al. 2022. J Immunother Cancer. 10:. PubMed
  134. AbuEid M, et al. 2021. iScience. 24(6):102653. PubMed
  135. Donnarumma T, et al. 2016. Cell Rep. 17:1571-1583. PubMed
  136. Shen T, et al. 2019. Cell Death Discov. 5:123. PubMed
  137. Huang X, et al. 2019. Cancer Immunol Res. 1.388888889. PubMed
  138. Leeansyah E, et al. 2015. PLoS Pathog. 11: 1005072. PubMed
  139. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  140. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  141. Ron–Harel N, et al. 2019. Cell Rep. 28:3011. PubMed
  142. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  143. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  144. Figueroa-Romero C, et al. 2022. Front Immunol. 13:773288. PubMed
  145. Di Blasi D, et al. 2019. Cell Mol Gastroenterol Hepatol. 0.510416667. PubMed
  146. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  147. Rafiq S, et al. 2018. Nat Biotechnol. 36:847. PubMed
  148. Peng Z, et al. 2021. STAR Protocols. 2(2):100595. PubMed
  149. Kramer KJ, et al. 2022. Nat Commun. 13:3466. PubMed
  150. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  151. Wu W, et al. 2020. Oncol Lett. 0.91875. PubMed
  152. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  153. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  154. Jiang P, et al. 2021. Nat Methods. 18:1181. PubMed
  155. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  156. Islas-Vazquez L, et al. 2020. Biology (Basel). 9:00. PubMed
  157. Kreutmair S, et al. 2021. Immunity. . PubMed
  158. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  159. Lucas C, et al. 2021. Nature. Online ahead of print. PubMed
  160. Adams NM et al. 2018. Immunity. 48(6):1172-1182 . PubMed
  161. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  162. Diaz–Salazar C, et al. 2020. Cell Rep. 32:108186. PubMed
  163. Fujigaki J, et al. 2015. PLoS One. 10: 0132521. PubMed
  164. Bastiaens G, et al. 2016. Am J Trop Med Hyg. 94: 663 - 673. PubMed
  165. Wiedemann GM, et al. 2020. Cell Rep. 33:108498. PubMed
  166. Huang CH, et al. 2020. Adv Ther (Weinh). 3:. PubMed
  167. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  168. Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed
  169. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  170. Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed
  171. Vardam-Kaur T, et al. 2021. Oncotarget. 12:2051. PubMed
  172. Xu S, et al. 2021. Immunity. . PubMed
  173. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  174. Bradley T et al. 2018. Cell. 175(2):387-399 . PubMed
  175. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  176. Luo Y, et al. 2021. Nat Commun. 12:3913. PubMed
  177. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  178. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  179. Leclerc M, et al. 2019. Nat Commun. 10:3345. PubMed
  180. Su S et al. 2018. Cell. 175(2):442-457 . PubMed
  181. Jeng MY, et al. 2018. J Exp Med. 215:51. PubMed
  182. Peluso MJ, et al. 2021. Cell Rep. 36:109518. PubMed
  183. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  184. Prado-Garcia H, et al. 2017. Cancer Immunol Immunother. 10.1007/s00262-017-1979-x. PubMed
  185. Wiede F, et al. 2014. J Autoimmun. 53:105. PubMed
  186. Kmieciak M, et al. 2011. J Immunol. 187:708. PubMed
  187. Zhang J, et al. 2018. Nature. 553:91. PubMed
  188. Kumagai S, et al. 2020. Immunity. 53(1):187-203.e8. PubMed
  189. Sagebiel AF, et al. 2019. Nat Commun. 10:975. PubMed
  190. Lettau M, et al. 2018. Int Immunol. 30:215. PubMed
  191. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  192. Thieme CJ, et al. 2020. Cell Rep Med. 1:100092. PubMed
  193. Yu M, et al. 2021. Molecular Cell. 81(6):1216-1230.e9. PubMed
  194. Maleki KT, et al. 2021. Cell Reports Medicine. 2(3):100220. PubMed
  195. Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed
  196. Dhar P, et al. 2021. Commun Biol. 4:905. PubMed
  197. Chen RH, et al. 2021. Front Immunol. 11:594775. PubMed
  198. Kansy BA, et al. 2017. Cancer Res. 77:6353. PubMed
  199. Hu X, et al. 2020. Neoplasia. 1.290972222. PubMed
  200. Sheppard S, et al. 2021. Cell Reports. 35(9):109210. PubMed
  201. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  202. Ajith A, et al. 2019. FASEB J. 33:5220. PubMed
  203. Geary CD et al. 2018. Cell reports. 24(8):1949-1957 . PubMed
  204. Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed
  205. DiMarco AV, et al. 2022. Cancer Immunol Res. 10:70. PubMed
  206. McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed
  207. Li Q, et al. 2022. J Biol Chem. :101753. PubMed
  208. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  209. Vonderhaar EP, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:41. PubMed
  210. Ruth JH, et al. 2021. JCI Insight. 6:e145662. PubMed
  211. Loo Yau H, et al. 2021. STAR Protocols. 2(2):100549. PubMed
  212. Loo Yau H, et al. 2021. Molecular Cell. 81(7):1469-1483.e8. PubMed
  213. Dubrot J, et al. 2021. Immunity. 54(3):571-585.e6. PubMed
  214. Durand J, et al. 2015. J Immunol. 195: 5035 - 5044. PubMed
  215. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  216. Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed
  217. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
  218. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  219. Carrion B, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  220. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
  221. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
  222. Gorby C, et al. 2020. Sci Signal. :13. PubMed
RRID
AB_2114575 (BioLegend Cat. No. 515403)

Antigen Details

Structure
32 kD serine protease
Distribution

Cytotoxic T-cells and NK cells, low on granulocytes, B cells and activated dendritic cells

Function
Induction of cell death and apoptosis
Ligand/Receptor
Mannose-6-phosphate receptor
Cell Type
B cells, Dendritic cells, NK cells, T cells
Biology Area
Cell Biology, Immunology, Innate Immunity, Neuroscience
Molecular Family
Enzymes and Regulators, Proteases
Antigen References

1. Estebanez-Perpina E, et al. 2000. Biol Chem. 381:1203
2. Griffiths GM. And S. Isaaz, et al. 1993. J. Cell Biol. 120:885
3. Spaeny-Dekking EH, et al. 1998. J. Immunol. 160:3610
4. Wagner C, et al. 2008. Mol. Immunol. 45:1761

Gene ID
3002 View all products for this Gene ID 14939 View all products for this Gene ID 171528 View all products for this Gene ID
UniProt
View information about Granzyme B on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 3    Revision Date: 08/25/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
GB11 (See other available formats)
Regulatory Status
RUO
Other Names
Granzyme-2, serine protease B, CCP1, Asp-ase, CTLA-1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
A_GB11_FITC_082409
Human peripheral blood lymphocytes surface stained with CD8 PE, then intracellular stained with GB11 FITC
  • A_GB11_FITC_082409
    Human peripheral blood lymphocytes surface stained with CD8 PE, then intracellular stained with GB11 FITC
  • B_GB11_FITC_082409
    Human peripheral blood lymphocytes surface stained with CD8 PE, then intracellular stained with mouse IgG1 FITC isotype control
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
515403 25 tests DKK796
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Granzyme B is a 32 kD serine protease, also known as granzyme-2, serine protease B, CCP1, Asp-ase, and CTLA-1. Granzyme B is abundantly stored in the granules of cytotoxic T lymphocytes and NK cells. Low level of expression has been reported in granulocytes, B cells, and activated dendritic cells. Granzyme B is crucial for rapid induction of cell death and apoptosis through interaction with mannose-6-phosphate receptor.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse
Reported Reactivity
Rat
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application References
  1. Wever PC, et al. 1998. Immunology. 93:383
  2. Arens R, et al. 2004. J. Exp. Med. 199:1595
  3. Lima M, et al. 2003. Am. J. Pathol. 163:763
  4. Wiede F, et al. 2014. J Autoimmun. 53:105. PubMed
  5. Baker GF, et al. 2014. Cancer Res. 74:5079. PubMed
  6. Nacer A, et al. 2014. PLoS Pathog. 10:1004528. PubMed
  7. Sharma SK, et al. 2015. J Immunol. 194:5529. PubMed
Product Citations
  1. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  2. Xiao C, et al. 2023. Nat Aging. 3:418. PubMed
  3. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  4. Ajith A, et al. 2021. Front Immunol. 12:687715. PubMed
  5. Xin B, et al. 2022. Hepatology. 76:630. PubMed
  6. Vorkas CK, et al. 2022. J Immunol. 208:1042. PubMed
  7. McMurray JL, et al. 2022. Cell Rep. 39:110858. PubMed
  8. Tan TCJ, et al. 2022. Nat Commun. 13:7796. PubMed
  9. An HW, et al. 2022. Cell Rep. 41:111878. PubMed
  10. Lin YH 2023. Immunity. 56(1):207-223.e8. PubMed
  11. Sieow JL, et al. 2023. Int J Mol Sci. 24: . PubMed
  12. Kuehm LM, et al. 2021. Cancer Immunol Res. 9:227. PubMed
  13. Drijvers JM, et al. 2021. Cancer Immunol Res. 9:184. PubMed
  14. Khojandi N, et al. 2021. Cancer Immunol Res. 9:214. PubMed
  15. Deng G, et al. 2022. J Immunother Cancer. 10:. PubMed
  16. Ou W, et al. 2023. Nat Commun. 14:392. PubMed
  17. Cheng MI, et al. 2023. Nat Immunol. 24:780. PubMed
  18. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  19. Baker G, et al. 2014. Cancer Res. 74:5079. PubMed
  20. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  21. Wang W, et al. 2022. World J Gastrointest Oncol. 14:1124. PubMed
  22. van Vloten JP, et al. 2022. J Immunother Cancer. 10:. PubMed
  23. AbuEid M, et al. 2021. iScience. 24(6):102653. PubMed
  24. Donnarumma T, et al. 2016. Cell Rep. 17:1571-1583. PubMed
  25. Shen T, et al. 2019. Cell Death Discov. 5:123. PubMed
  26. Huang X, et al. 2019. Cancer Immunol Res. 1.388888889. PubMed
  27. Leeansyah E, et al. 2015. PLoS Pathog. 11: 1005072. PubMed
  28. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  29. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  30. Ron–Harel N, et al. 2019. Cell Rep. 28:3011. PubMed
  31. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  32. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  33. Figueroa-Romero C, et al. 2022. Front Immunol. 13:773288. PubMed
  34. Di Blasi D, et al. 2019. Cell Mol Gastroenterol Hepatol. 0.510416667. PubMed
  35. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  36. Rafiq S, et al. 2018. Nat Biotechnol. 36:847. PubMed
  37. Peng Z, et al. 2021. STAR Protocols. 2(2):100595. PubMed
  38. Kramer KJ, et al. 2022. Nat Commun. 13:3466. PubMed
  39. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  40. Wu W, et al. 2020. Oncol Lett. 0.91875. PubMed
  41. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  42. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  43. Jiang P, et al. 2021. Nat Methods. 18:1181. PubMed
  44. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  45. Islas-Vazquez L, et al. 2020. Biology (Basel). 9:00. PubMed
  46. Kreutmair S, et al. 2021. Immunity. . PubMed
  47. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  48. Lucas C, et al. 2021. Nature. Online ahead of print. PubMed
  49. Adams NM et al. 2018. Immunity. 48(6):1172-1182 . PubMed
  50. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  51. Diaz–Salazar C, et al. 2020. Cell Rep. 32:108186. PubMed
  52. Fujigaki J, et al. 2015. PLoS One. 10: 0132521. PubMed
  53. Bastiaens G, et al. 2016. Am J Trop Med Hyg. 94: 663 - 673. PubMed
  54. Wiedemann GM, et al. 2020. Cell Rep. 33:108498. PubMed
  55. Huang CH, et al. 2020. Adv Ther (Weinh). 3:. PubMed
  56. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  57. Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed
  58. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  59. Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed
  60. Vardam-Kaur T, et al. 2021. Oncotarget. 12:2051. PubMed
  61. Xu S, et al. 2021. Immunity. . PubMed
  62. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  63. Bradley T et al. 2018. Cell. 175(2):387-399 . PubMed
  64. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  65. Luo Y, et al. 2021. Nat Commun. 12:3913. PubMed
  66. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  67. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  68. Leclerc M, et al. 2019. Nat Commun. 10:3345. PubMed
  69. Su S et al. 2018. Cell. 175(2):442-457 . PubMed
  70. Jeng MY, et al. 2018. J Exp Med. 215:51. PubMed
  71. Peluso MJ, et al. 2021. Cell Rep. 36:109518. PubMed
  72. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  73. Prado-Garcia H, et al. 2017. Cancer Immunol Immunother. 10.1007/s00262-017-1979-x. PubMed
  74. Wiede F, et al. 2014. J Autoimmun. 53:105. PubMed
  75. Kmieciak M, et al. 2011. J Immunol. 187:708. PubMed
  76. Zhang J, et al. 2018. Nature. 553:91. PubMed
  77. Kumagai S, et al. 2020. Immunity. 53(1):187-203.e8. PubMed
  78. Sagebiel AF, et al. 2019. Nat Commun. 10:975. PubMed
  79. Lettau M, et al. 2018. Int Immunol. 30:215. PubMed
  80. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  81. Thieme CJ, et al. 2020. Cell Rep Med. 1:100092. PubMed
  82. Yu M, et al. 2021. Molecular Cell. 81(6):1216-1230.e9. PubMed
  83. Maleki KT, et al. 2021. Cell Reports Medicine. 2(3):100220. PubMed
  84. Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed
  85. Dhar P, et al. 2021. Commun Biol. 4:905. PubMed
  86. Chen RH, et al. 2021. Front Immunol. 11:594775. PubMed
  87. Kansy BA, et al. 2017. Cancer Res. 77:6353. PubMed
  88. Hu X, et al. 2020. Neoplasia. 1.290972222. PubMed
  89. Sheppard S, et al. 2021. Cell Reports. 35(9):109210. PubMed
  90. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  91. Ajith A, et al. 2019. FASEB J. 33:5220. PubMed
  92. Geary CD et al. 2018. Cell reports. 24(8):1949-1957 . PubMed
  93. Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed
  94. DiMarco AV, et al. 2022. Cancer Immunol Res. 10:70. PubMed
  95. McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed
  96. Li Q, et al. 2022. J Biol Chem. :101753. PubMed
  97. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  98. Vonderhaar EP, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:41. PubMed
  99. Ruth JH, et al. 2021. JCI Insight. 6:e145662. PubMed
  100. Loo Yau H, et al. 2021. STAR Protocols. 2(2):100549. PubMed
  101. Loo Yau H, et al. 2021. Molecular Cell. 81(7):1469-1483.e8. PubMed
  102. Dubrot J, et al. 2021. Immunity. 54(3):571-585.e6. PubMed
  103. Durand J, et al. 2015. J Immunol. 195: 5035 - 5044. PubMed
  104. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  105. Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed
  106. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
  107. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  108. Carrion B, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  109. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
  110. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
  111. Gorby C, et al. 2020. Sci Signal. :13. PubMed
  112. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  113. Xiao C, et al. 2023. Nat Aging. 3:418. PubMed
  114. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  115. Ajith A, et al. 2021. Front Immunol. 12:687715. PubMed
  116. Xin B, et al. 2022. Hepatology. 76:630. PubMed
  117. Vorkas CK, et al. 2022. J Immunol. 208:1042. PubMed
  118. McMurray JL, et al. 2022. Cell Rep. 39:110858. PubMed
  119. Tan TCJ, et al. 2022. Nat Commun. 13:7796. PubMed
  120. An HW, et al. 2022. Cell Rep. 41:111878. PubMed
  121. Lin YH 2023. Immunity. 56(1):207-223.e8. PubMed
  122. Sieow JL, et al. 2023. Int J Mol Sci. 24: . PubMed
  123. Kuehm LM, et al. 2021. Cancer Immunol Res. 9:227. PubMed
  124. Drijvers JM, et al. 2021. Cancer Immunol Res. 9:184. PubMed
  125. Khojandi N, et al. 2021. Cancer Immunol Res. 9:214. PubMed
  126. Deng G, et al. 2022. J Immunother Cancer. 10:. PubMed
  127. Ou W, et al. 2023. Nat Commun. 14:392. PubMed
  128. Cheng MI, et al. 2023. Nat Immunol. 24:780. PubMed
  129. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  130. Baker G, et al. 2014. Cancer Res. 74:5079. PubMed
  131. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  132. Wang W, et al. 2022. World J Gastrointest Oncol. 14:1124. PubMed
  133. van Vloten JP, et al. 2022. J Immunother Cancer. 10:. PubMed
  134. AbuEid M, et al. 2021. iScience. 24(6):102653. PubMed
  135. Donnarumma T, et al. 2016. Cell Rep. 17:1571-1583. PubMed
  136. Shen T, et al. 2019. Cell Death Discov. 5:123. PubMed
  137. Huang X, et al. 2019. Cancer Immunol Res. 1.388888889. PubMed
  138. Leeansyah E, et al. 2015. PLoS Pathog. 11: 1005072. PubMed
  139. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  140. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  141. Ron–Harel N, et al. 2019. Cell Rep. 28:3011. PubMed
  142. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  143. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  144. Figueroa-Romero C, et al. 2022. Front Immunol. 13:773288. PubMed
  145. Di Blasi D, et al. 2019. Cell Mol Gastroenterol Hepatol. 0.510416667. PubMed
  146. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  147. Rafiq S, et al. 2018. Nat Biotechnol. 36:847. PubMed
  148. Peng Z, et al. 2021. STAR Protocols. 2(2):100595. PubMed
  149. Kramer KJ, et al. 2022. Nat Commun. 13:3466. PubMed
  150. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  151. Wu W, et al. 2020. Oncol Lett. 0.91875. PubMed
  152. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  153. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  154. Jiang P, et al. 2021. Nat Methods. 18:1181. PubMed
  155. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  156. Islas-Vazquez L, et al. 2020. Biology (Basel). 9:00. PubMed
  157. Kreutmair S, et al. 2021. Immunity. . PubMed
  158. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  159. Lucas C, et al. 2021. Nature. Online ahead of print. PubMed
  160. Adams NM et al. 2018. Immunity. 48(6):1172-1182 . PubMed
  161. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  162. Diaz–Salazar C, et al. 2020. Cell Rep. 32:108186. PubMed
  163. Fujigaki J, et al. 2015. PLoS One. 10: 0132521. PubMed
  164. Bastiaens G, et al. 2016. Am J Trop Med Hyg. 94: 663 - 673. PubMed
  165. Wiedemann GM, et al. 2020. Cell Rep. 33:108498. PubMed
  166. Huang CH, et al. 2020. Adv Ther (Weinh). 3:. PubMed
  167. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  168. Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed
  169. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  170. Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed
  171. Vardam-Kaur T, et al. 2021. Oncotarget. 12:2051. PubMed
  172. Xu S, et al. 2021. Immunity. . PubMed
  173. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  174. Bradley T et al. 2018. Cell. 175(2):387-399 . PubMed
  175. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  176. Luo Y, et al. 2021. Nat Commun. 12:3913. PubMed
  177. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  178. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  179. Leclerc M, et al. 2019. Nat Commun. 10:3345. PubMed
  180. Su S et al. 2018. Cell. 175(2):442-457 . PubMed
  181. Jeng MY, et al. 2018. J Exp Med. 215:51. PubMed
  182. Peluso MJ, et al. 2021. Cell Rep. 36:109518. PubMed
  183. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  184. Prado-Garcia H, et al. 2017. Cancer Immunol Immunother. 10.1007/s00262-017-1979-x. PubMed
  185. Wiede F, et al. 2014. J Autoimmun. 53:105. PubMed
  186. Kmieciak M, et al. 2011. J Immunol. 187:708. PubMed
  187. Zhang J, et al. 2018. Nature. 553:91. PubMed
  188. Kumagai S, et al. 2020. Immunity. 53(1):187-203.e8. PubMed
  189. Sagebiel AF, et al. 2019. Nat Commun. 10:975. PubMed
  190. Lettau M, et al. 2018. Int Immunol. 30:215. PubMed
  191. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  192. Thieme CJ, et al. 2020. Cell Rep Med. 1:100092. PubMed
  193. Yu M, et al. 2021. Molecular Cell. 81(6):1216-1230.e9. PubMed
  194. Maleki KT, et al. 2021. Cell Reports Medicine. 2(3):100220. PubMed
  195. Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed
  196. Dhar P, et al. 2021. Commun Biol. 4:905. PubMed
  197. Chen RH, et al. 2021. Front Immunol. 11:594775. PubMed
  198. Kansy BA, et al. 2017. Cancer Res. 77:6353. PubMed
  199. Hu X, et al. 2020. Neoplasia. 1.290972222. PubMed
  200. Sheppard S, et al. 2021. Cell Reports. 35(9):109210. PubMed
  201. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  202. Ajith A, et al. 2019. FASEB J. 33:5220. PubMed
  203. Geary CD et al. 2018. Cell reports. 24(8):1949-1957 . PubMed
  204. Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed
  205. DiMarco AV, et al. 2022. Cancer Immunol Res. 10:70. PubMed
  206. McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed
  207. Li Q, et al. 2022. J Biol Chem. :101753. PubMed
  208. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  209. Vonderhaar EP, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:41. PubMed
  210. Ruth JH, et al. 2021. JCI Insight. 6:e145662. PubMed
  211. Loo Yau H, et al. 2021. STAR Protocols. 2(2):100549. PubMed
  212. Loo Yau H, et al. 2021. Molecular Cell. 81(7):1469-1483.e8. PubMed
  213. Dubrot J, et al. 2021. Immunity. 54(3):571-585.e6. PubMed
  214. Durand J, et al. 2015. J Immunol. 195: 5035 - 5044. PubMed
  215. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  216. Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed
  217. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
  218. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  219. Carrion B, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  220. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
  221. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
  222. Gorby C, et al. 2020. Sci Signal. :13. PubMed
RRID
AB_2114575 (BioLegend Cat. No. 515403)

Antigen Details

Structure
32 kD serine protease
Distribution

Cytotoxic T-cells and NK cells, low on granulocytes, B cells and activated dendritic cells

Function
Induction of cell death and apoptosis
Ligand/Receptor
Mannose-6-phosphate receptor
Cell Type
B cells, Dendritic cells, NK cells, T cells
Biology Area
Cell Biology, Immunology, Innate Immunity, Neuroscience
Molecular Family
Enzymes and Regulators, Proteases
Antigen References

1. Estebanez-Perpina E, et al. 2000. Biol Chem. 381:1203
2. Griffiths GM. And S. Isaaz, et al. 1993. J. Cell Biol. 120:885
3. Spaeny-Dekking EH, et al. 1998. J. Immunol. 160:3610
4. Wagner C, et al. 2008. Mol. Immunol. 45:1761

Gene ID
3002 View all products for this Gene ID 14939 View all products for this Gene ID 171528 View all products for this Gene ID
UniProt
View information about Granzyme B on UniProt.org
Go To Top Version: 3    Revision Date: 08/25/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account